融券方面，赛分科技11月20日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量0.00股，融券余额0.00元。 资料显示，苏州赛分科技股份有限公司位于中国(江苏)自由贸易试验区苏州片区苏州工业园区集贤街11 号，成立日期2009年3月16日，上市日期2025年1月10日，公司主营业务涉及研发和生产用于药物分析检 测和分离纯化的液相色谱材料。主营业务收入构成为：工业纯化板块33.10%，工业纯化板块:填料 32.65%，分析色谱板块16.73%，分析色谱板块:色谱柱13.31%，分析色谱板块:填料3.13%，分析色谱板 块:其他0.29%，工业纯化板块:其他0.27%，其他(补充)0.18%，工业纯化板块:色谱柱0.18%，服务 0.15%。 11月20日，赛分科技涨0.70%，成交额7115.39万元。两融数据显示，当日赛分科技获融资买入额402.57 万元，融资偿还1221.17万元，融资净买入-818.60万元。截至11月20日，赛分科技融资融券余额合计 7727.55万元。 融资方面，赛分科技当日融资买入402.57万元。当前融资余额7727.55万元，占流通市值 ...

Group 1 - The core point of the news is that Saifen Technology has seen a stock price increase of 5.51%, reaching 23.36 CNY per share, with a total market capitalization of 9.729 billion CNY [1] - Saifen Technology, established on March 16, 2009, specializes in the research and production of liquid chromatography materials for drug analysis and purification [1] - The company's main business revenue breakdown includes: Industrial Purification Segment 33.10%, Industrial Purification Fillers 32.65%, Analytical Chromatography Segment 16.73%, Analytical Chromatography Columns 13.31%, Analytical Chromatography Fillers 3.13%, and other segments contributing smaller percentages [1] Group 2 - According to data, one fund from GF Fund has Saifen Technology as its second-largest holding, with 777 shares held unchanged from the previous period [2] - The fund, GF CSI A500 ETF Link A (022424), has a total scale of 3.321 billion CNY and has achieved a year-to-date return of 23.59% [2] - The fund manager, Lu Zhimin, has a tenure of 14 years and 169 days, with the fund's total asset scale at 24.063 billion CNY [3]

Core Points - The Sci-Tech Innovation Board (STAR Market) index rose by 1.44%, closing at 1399.29 points, with a total trading volume of 4.357 billion shares and a turnover of 189.525 billion yuan [1] - Among the tradable stocks on the STAR Market, 419 stocks closed higher, with 11 stocks experiencing a rise of over 10%, including Kangpeng Technology, Haibo Sichuang, and Huasheng Lithium, which hit the daily limit [1] - The turnover rate for STAR Market stocks showed that 3 stocks had a turnover rate exceeding 20%, while 21 stocks had a turnover rate between 10% and 20% [1] Trading Performance - The highest turnover rate was recorded by Haibo Sichuang at 22.07%, with a closing price increase of 20.00% and a trading volume of 2.869 billion yuan [1][3] - Other notable stocks with high turnover rates included Saifen Technology (21.43% turnover rate, 10.92% increase) and Kangpeng Technology (20.48% turnover rate, 20.02% increase) [3][4] - The stocks with the largest net inflow of funds included Haibo Sichuang (281.31 million yuan), Changguang Huaxin (166.1 million yuan), and Huasheng Lithium (88.835 million yuan) [2] Sector Analysis - In terms of industry distribution, the electronics sector had the most stocks with a turnover rate exceeding 5%, totaling 20 stocks, followed by power equipment and pharmaceutical biotechnology with 18 and 9 stocks, respectively [2] - The stocks with significant net outflows included Artis (454 million yuan), Yuanjie Technology (185 million yuan), and Baiwei Storage (168 million yuan) [2] Recent Trends - As of November 12, the stocks with the largest increase in financing balance over the past five days included Purun Co. (271 million yuan), Yuanjie Technology (252 million yuan), and Shenkong Co. (223 million yuan) [2] - Conversely, the stocks with the largest decrease in financing balance included Foxit Software (192 million yuan), New Xiangwei (184 million yuan), and Jucheng Co. (117 million yuan) [2]

Group 1 - The core viewpoint of the news is that Sai Fen Technology's stock performance and financial metrics indicate a mixed outlook, with a slight decline in stock price and notable financing activities [1][2]. Group 2 - On November 12, Sai Fen Technology's stock price decreased by 0.30%, with a trading volume of 58.96 million yuan. The financing buy-in amount was 4.28 million yuan, while the financing repayment was 6.13 million yuan, resulting in a net financing buy-in of -1.85 million yuan [1]. - As of November 12, the total financing and securities lending balance for Sai Fen Technology was 74.42 million yuan, accounting for 8.78% of its circulating market value [1]. - The company has not engaged in any securities lending activities on November 12, with no shares sold or repaid [1]. Group 3 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2]. - The company's revenue composition includes: Industrial Purification Segment (33.10%), Fillers (32.65%), Analytical Chromatography Segment (16.73%), Chromatography Columns (13.31%), and other minor segments [2]. - For the period from January to September 2025, Sai Fen Technology achieved a revenue of 302 million yuan, representing a year-on-year growth of 38.39%, and a net profit attributable to shareholders of 93.21 million yuan, with a year-on-year increase of 71.07% [2]. Group 4 - Since its A-share listing, Sai Fen Technology has distributed a total of 27.90 million yuan in dividends [3]. - As of September 30, 2025, the number of shareholders decreased by 31.51% to 7,159, while the average circulating shares per person increased by 57.01% to 5,933 shares [2][3].

Group 1 - The core viewpoint of the news highlights the performance and financial metrics of Sai Fen Technology, including stock price increase and trading volume [1] - On November 11, Sai Fen Technology's stock rose by 4.60%, with a trading volume of 102 million yuan and a net financing purchase of 1.7166 million yuan [1] - As of November 11, the total margin balance for Sai Fen Technology was 76.2679 million yuan, accounting for 8.97% of its market capitalization [1] Group 2 - Sai Fen Technology, established on March 16, 2009, is located in the Suzhou Industrial Park and specializes in the research and production of liquid chromatography materials for drug analysis and purification [2] - The company's revenue composition includes 33.10% from industrial purification, 32.65% from fillers, and 16.73% from analytical chromatography, among other segments [2] - For the period from January to September 2025, Sai Fen Technology achieved a revenue of 302 million yuan, representing a year-on-year growth of 38.39%, and a net profit of 93.2118 million yuan, with a growth of 71.07% [2] Group 3 - Since its A-share listing, Sai Fen Technology has distributed a total of 27.9031 million yuan in dividends [3] - As of September 30, 2025, the number of shareholders decreased by 31.51% to 7,159, while the average circulating shares per person increased by 57.01% to 5,933 shares [2][3] - Notably, the Southern Science and Technology Innovation Board 3-Year Open Mixed Fund has exited the top ten circulating shareholders list [3]

赛分科技 20251107 摘要 赛峰科技前三季度工业纯化板块收入 12.08 亿元，同比增长 68.08%， 占主营收入 69%；归母净利润 9,321.18 万元，同比增长 71.07%。受 益于新增客户拓展和存量客户复购，公司经营规模扩张，但需关注重组 蛋白领域收入同比下降。 工业纯化板块中，抗体药物领域收入占比 60.62%，胰岛素多肽 GLP-1 领域收入占比 35.41%，同比增速 161.44%。GLP-1 领域增长迅速， 成为重要增长点，但需关注其他领域发展。 截至 2025 年 9 月 30 日，公司累计项目数量 1,126 个，其中研发阶段 893 个，临床阶段约 170 个，商业化生产 60 个。新增项目主要集中在 研发阶段，预示未来增长潜力，但商业化转化率是关键。 国产填料价格约为进口填料的 40%-50%，市场价格有所下降，预计明 年部分厂家会进一步压低价格。公司色谱填料毛利率维持在 70%左右， 药企更注重安全性，规模化企业竞争优势明显。 前三季度商业化阶段收入贡献约 1.223 亿元，占纯化业务收入近 60%；临床三期收入占比 18.57%。临床后期和商业化阶段收入贡献占 比约 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 会议召开时间：2025年11月17日（星期一）15:00-16:00 ● 会议召开地点：价值在线（www.ir-online.cn） ● 会议召开方式：网络互动方式 ● 会议问题征集：投资者可于2025年11月17日15:00前访问网址https://eseb.cn/1t07bRb4WVq或使用微信 扫描下方小程序码进行会前提问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍关 注的问题进行回答。 ■ 一、说明会类型 苏州赛分科技股份有限公司（以下简称"公司"）已于2025年10月28日在上海证券交易所网站 （www.sse.com.cn）披露了《苏州赛分科技股份有限公司2025年第三季度报告》。为便于广大投资者更 加全面深入地了解公司经营业绩、发展战略等情况，公司定于2025年11月17日（星期一）15:00-16:00 在"价值在线"（www.ir-online.cn）举办公司2025年第三 ...

证券代码：688758 证券简称：赛分科技 公告编号：2025-039 苏州赛分科技股份有限公司 关于召开2025年第三季度业绩说明会的公 告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、说明会类型 苏州赛分科技股份有限公司（以下简称"公司"）已于 2025 年 10 月 28 日 在上海证券交易所网站（www.sse.com.cn）披露了《苏州赛分科技股份有限公司 2025 年第三季度报告》。为便于广大投资者更加全面深入地了解公司经营业绩、 会议召开时间：2025 年 11 月 17 日（星期一）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会议问题征集：投资者可于 2025 年 11 月 17 日 15:00 前访问网址 https://eseb.cn/1t07bRb4WVq 或使用微信扫描下方小程序码进行会前提 问，公司将通过本次业绩说明会，在信息披露允许范围内就投资者普遍 关注的问题进行回答。 二、说明会召开的时间、地点和方式 ...

Core Viewpoint - The company has reported a total asset impairment provision of 11.54 million yuan for the first three quarters of 2025, which will reduce the total profit for the same period by the same amount [8][11]. Financial Data - The financial statements for the third quarter of 2025 have not been audited [3][4]. - The company has confirmed that the financial information in the quarterly report is true, accurate, and complete [2]. Asset Impairment Provision - The company conducted impairment testing on its assets as of September 30, 2025, and recognized a total asset impairment provision of 11.54 million yuan [8]. - The breakdown of the impairment includes: - Credit impairment losses amounting to 5.67 million yuan [9]. - Asset impairment losses related to inventory amounting to 5.88 million yuan [10]. Impact on Financial Performance - The total asset impairment and credit impairment losses will decrease the company's total profit for the first three quarters of 2025 by 11.54 million yuan, not accounting for income tax effects [11].

Core Viewpoint - SaiFen Technology, a leading domestic liquid chromatography material company, reported strong financial performance for the first three quarters of 2025, with revenue of 302 million yuan, a year-on-year increase of 38.39%, and a net profit attributable to shareholders of 93.21 million yuan, up 71.07% year-on-year, indicating robust growth driven by the demand for chromatography fillers in the biopharmaceutical sector [1][2]. Financial Performance - The company achieved a net profit of 39.55 million yuan in the third quarter alone, reflecting a remarkable year-on-year growth of 141.05% [1]. - The profit growth rate significantly outpaced revenue growth, showcasing the company's transition from technological breakthroughs to large-scale production [1]. Market Demand and Industry Trends - The demand for chromatography fillers is characterized by strong rigidity, essential for drug research, quality testing, and commercial production, particularly as domestic biopharmaceutical companies transition from clinical stages to commercialization [1][2]. - The domestic biopharmaceutical chromatography filler market is expected to grow significantly over the next 3 to 5 years, with procurement volumes projected to increase several times as many drug companies' research projects enter the commercialization phase [2]. Technological Advancements - SaiFen Technology's growth is supported by a robust technological foundation, with R&D investment reaching 40.60 million yuan, a year-on-year increase of 20.37%, and over 80 authorized patents [2]. - The company has developed high-performance products like MabPurixInfiniteA, which meet downstream efficiency and cost requirements, optimizing its offerings towards high-margin areas [2]. Global Expansion Strategy - The company is pursuing international expansion through various models, including direct sales and establishing a production base in the U.S., aiming to create a dual capacity structure that serves both domestic and global markets [3]. - SaiFen Technology has a history of international presence, having established its U.S. brand "Sepax" in 2002, and the recent establishment of SaiFen Biotech in 2022 is expected to enhance supply chain stability for global clients [3]. Competitive Positioning - The company is well-positioned to benefit from the domestic substitution trend, as the chromatography filler market has historically been dominated by international giants, with current domestic market penetration still low [2][3]. - With the backdrop of self-sufficiency in the biopharmaceutical supply chain, SaiFen Technology is expected to experience significant growth and value re-evaluation as it capitalizes on both domestic and international market opportunities [3].